TABLE II.
Lipid mediator levels in controls, patients with CRSwNP, and patients with AERD
| Mediator | Control (n = 33) | CRSwNP (n = 34) | AERD (n = 30) | P value |
|---|---|---|---|---|
| 12,13-EpOME | 11,359 (7,953-19,637) | 8,591 (4,846-14,877) | 5,782 (2,737-12,313)* | .005 |
| 9,10-DiHOME | 15.8 (9.4-26.6) | 11.4 (8.9-11.4) | 5.4 (2.7-23.4)*† | .003 |
| 12,13-DiHOME | 23.4 (14.4-41.3) | 27.6 (19.9-40.7) | 1.5 (0.01-4.1)*† | <.001 |
| 9,10-EpOME | 1,150 (687.9-3,835) | 652 (394.5-929.7)* | 249 (156-450)*† | <.001 |
| 13-HODE | 9,804 (6,807-16,566) | 7,335 (4,228-12,482) | 8,852 (4,163-16,605) | .17 |
| 8-HETE | 86.0 (68.6-136.7) | 55.0 (36.8-103.6) | 29.0 (14.8-64.0)*† | <.001 |
| 15-HETE | 8,259 (5,359-10,414) | 6,554 (4,050-9,011) | 3,496 (1,795-6,715) | .006 |
| 12-HETE | 921.7 (658.1-1,210) | 676.5 (406.4-945.0) | 474.2 (216.9-595.6)*† | <.001 |
| 11,12-EET | 1,295 (845-5,892) | 856.5 (587.5-1,289) | 228.3 (164.1-336.4)*† | <.001 |
| 14,15-EET | 1,688 (1,115-2,583) | 1,267 (697-1,629) | 725 (467-981)*† | <.001 |
| 20-HETE | 181,126 (99,675-253,998) | 152,415 (82,825-188,409) | 61,850 (36,426-117,669)*† | <.001 |
| TxB2 | 4.9 (1.4-16.5) | 6.3 (1.2-15.6) | 16.9 (6.2-47.9)*† | .003 |
| PGD2 | 6.3 (4.0-13.3) | 21.1 (11.1-41.6)* | 28.1 (15.0-63.8)* | <.001 |
| 15-Keto-PGE2 | 0.77 (0.41-1.30) | 0.97 (0.39-1.53) | 1.36 (0.67-1.82)* | .03 |
| PGE2 | 105.0 (68.1-137.6) | 73.8 (56.3-149.9) | 98.4 (49.5-149.8) | .92 |
| PGF2a | 18.4 (12.9-35.7) | 15.7 (9.6-20.5) | 9.5 (0.01-16.8)* | .001 |
| 9a,11b-PGF2a | 1.3 (0.3-3.7) | 3.0 (1.7-9.8) | 9.7 (0.01-20.9)* | .005 |
| LTB4 | 12.7 (9.3-22.1) | 11.1 (5.6-24.3) | 0.01 (0.01-11.3)*† | <.001 |
| LTC4 | 31.9 (13.8-59.2) | 53.0 (27.6-80.0) | 32.0 (14.9-72.0) | .16 |
| LTD4 | 0.01 (0.01-0.34) | 0.23 (0.01-1.14) | 1.51 (0.01-2.65)* | <.001 |
| LTE4 | 0.17 (0.03-0.40) | 0.62 (0.16-2.78)* | 4.97 (1.87-12.75)*† | <.001 |
| Total CysLTs | 33.0 (16.9-60.4) | 55.7 (34.3-87.1) | 43.9 (21.3-79.2) | .10 |
Mucus levels of lipid mediators are shown for each group. All mediator levels are presented as ng/mL. Significant differences between groups were identified by the Kruskal-Wallis test followed by Dunn’s test for multiple comparisons. Data are presented as medians with interquartile range. Boldface text indicates P value of less than .05.
*
P < .05 compared with controls.
†
P < .05 compared with patients with CRSwNP.